Hot Integrated Utility Stocks To Own Right Now

Hot Integrated Utility Stocks To Own Right Now: Regeneron Pharmaceuticals Inc.(REGN)

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company?s commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical development stage consist of VEGF Trap-Eye, an aflibercept ophthalmic solution developed using intraocular delivery for the treatment of serious eye diseases; ARCALYST for the prevention of gout flares in patients initiating uric acid-lowering treatment; and Aflibercept (VEGF Trap), which is developed in oncology. The company?s earlier stage clinical programs include various human antibodies, such as REGN727 for low-density lipoprotein cholesterol reduction, REGN88 for rheumatoid arthritis and ankylosing spondylitis; REGN668 for atopic dermatitis and asthma; REGN421 and REGN910 for oncology; REGN475 for the treatment of pain; and REGN728 and REGN846. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with sanofi-aventis Group to discover, develop, and commercialize human monoclonal antibodies; and Bayer HealthCare LLC to develop and commercialize VEGF Trap. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is based in Tarrytown, New York.

Advisors' Opinion:

• [By Jon C. Ogg]

  RegeneronPharmaceuticals Inc. (NASDAQ: REGN) was started with an Outperform rating a! nd a $300 price target at Oppenheimer.

  SempraEnergy (NYSE: SRE) was started as Buy at KeyBanc Capital Markets.

• [By Ben Levisohn]

  Earlier today, the S&P 500 looked like it would close at an all-time high. Then the bears roared, and S&P 500 gave back about half its gains despite big moves in United Health (UNH), Humana (HUM), Pioneer Natural Resources (PXD),ExxonMobil (XOM) and Regeneron (REGN).

• [By Brian Orelli]

  Of course, shorting every FDA approval won't work and could be very costly. Check out Regeneron Pharmaceuticals (NASDAQ: REGN  ) after the November 2011 approval of its macular degeneration drug, Eylea. Once prescription and sales data started rolling in -- smashing investors' expectations -- shares zoomed higher.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/hot-integrated-utility-stocks-to-own-right-now-3.html